The cost of mass drug administration for trachoma in two counties of the Republic of South Sudan.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2024
Historique:
received: 21 07 2023
accepted: 12 06 2024
medline: 19 7 2024
pubmed: 19 7 2024
entrez: 19 7 2024
Statut: epublish

Résumé

Community-wide distribution of azithromycin, otherwise known as mass drug administration (MDA), is a component of the World Health Organization-endorsed SAFE strategy for the elimination of trachoma as a public health problem. In the Republic of South Sudan, 2.9 million people are known to live in areas that are known to require interventions and warrant MDA. This study estimated the total costs and cost per person treated during MDA in two counties, Kapoeta North and Kapoeta East, in South Sudan. MDA was conducted in Kapoeta North and Kapoeta East counties from October 2020 to January 2021. Following training and community sensitization, a core team, consisting of a height measurer, a drug dispenser, and a data recorder, delivered the intervention. A detailed costing database was developed in Microsoft Excel. An ingredients approach was used to capture all financial and economic costs incurred from a payer perspective. Primary outcomes included the total cost of MDA in each county and the cost per person treated in each county. In Kapoeta North, 58,226 people were treated at a financial cost of $71,350 USD. This corresponds to a unit cost of $1.22 per person treated. The total economic cost of the intervention was $99,036, at a unit cost of $1.70 per person treated. In Kapoeta East, 156,092 people were treated at a total financial cost of $168,404. This corresponds to a unit cost of $1.08 per person treated. The total economic cost of the intervention was $243,205, at a unit cost of $1.56 per person treated. The study highlights the cost variation for MDA implementation across two counties of South Sudan. As the South Sudan trachoma program expands, this information will be valuable for program planning.

Identifiants

pubmed: 39028729
doi: 10.1371/journal.pgph.0003242
pii: PGPH-D-23-01273
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e0003242

Informations de copyright

Copyright: © 2024 Jesudason et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

This study was led by an independent consultant with funding from The Carter Center.

Auteurs

Tim Jesudason (T)

Partners in Global Health Ltd, Dereham, United Kingdom.

Angelia M Sanders (AM)

The Carter Center, Atlanta, Georgia, United States of America.

Stephen Ohidor (S)

The Carter Center, Juba, Republic of South Sudan.

Alexis S Delahunt (AS)

The Carter Center, Atlanta, Georgia, United States of America.

Andrew R Deathe (AR)

The Carter Center, Atlanta, Georgia, United States of America.

Lochebe Boniface (L)

The Carter Center, Juba, Republic of South Sudan.

Isaiah Buot (I)

The Carter Center, Juba, Republic of South Sudan.

Mekete Bikis (M)

The Carter Center, Juba, Republic of South Sudan.

Samual Makoy (S)

The Ministry of Health, Juba, Republic of South Sudan.

Yak Yak Bol (YY)

The Ministry of Health, Juba, Republic of South Sudan.

James Niquette (J)

The Carter Center, Juba, Republic of South Sudan.

E Kelly Callahan (EK)

The Carter Center, Atlanta, Georgia, United States of America.

Damien Walker (D)

Independent Contractor, Arlington, VA, United States of America.

Scott D Nash (SD)

The Carter Center, Atlanta, Georgia, United States of America.

Classifications MeSH